Skip to main content
Fig. 3 | Journal of Nanobiotechnology

Fig. 3

From: Specific drug delivery efficiently induced human breast tumor regression using a lipoplex by non-covalent association with anti-tumor antibodies

Fig. 3

Cytotoxic effects of Cur/LPPC/Herceptin on HER2-negative or HER2-positive cell lines. Hs578T (HER2−), MDA-MB-231 (HER2 −/+), MCF7 (HER2+), and SKBR-3 (HER2++) cells were treated with 0 to 2.5 μM curcumin for the treatment of Cur/LPPC/Herceptin for 48 h. The dosages of LPPC, Herceptin, and LPPC/Herceptin were the same as those used for the Cur/LPPC/Herceptin treatments. Cell viability was assessed by MTT assay. All values represent the mean ± SD (n = 6)

Back to article page

Journal of Nanobiotechnology

ISSN: 1477-3155

Contact us